5JU0 Stock Overview
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Kiromic BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.10 |
| 52 Week High | US$18.45 |
| 52 Week Low | US$3.65 |
| Beta | 0.18 |
| 1 Month Change | 0% |
| 3 Month Change | -10.10% |
| 1 Year Change | -72.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JU0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | 1.1% |
| 1Y | -72.7% | -24.9% | 6.5% |
Return vs Industry: 5JU0 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 5JU0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 5JU0 volatility | |
|---|---|
| 5JU0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5JU0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 5JU0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 31 | Pietro Bersani | kiromic.com |
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L.
Kiromic BioPharma, Inc. Fundamentals Summary
| 5JU0 fundamental statistics | |
|---|---|
| Market cap | €2.77m |
| Earnings (TTM) | -€30.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 5JU0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JU0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.01m |
| Earnings | -US$33.01m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -33.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -122.6% |
How did 5JU0 perform over the long term?
See historical performance and comparison